Previous close | 2.0350 |
Open | 2.1300 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 2.1291 - 2.1300 |
52-week range | 1.3488 - 3.8550 |
Volume | |
Avg. volume | 2,340 |
Market cap | N/A |
Beta (5Y monthly) | 1.51 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2040 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Reiterating cash runway of > 2 yearsJERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment is triggered by the delivery of final clinical study reports for the completed FU
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would trigger a $10 million development milestone payment to SCYNEXISSCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of $94.2 million and projects a cash runway of more than two years JERSEY CITY, N.J.,
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...